Pharvaris is focused on bringing an oral bradykinin B2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (HAE) and other B2 receptor-mediated indications. Pharvaris uses small molecules to advance potent, orally available compounds targeting HAE. POC was demonstrated in a monkey model and it’s applicable to all patients in HAE. The company was founded by the former founders of Prosensa and Jerini and reunites the core team responsible for the discovery and approval of the HAE treatment icatibant.
Leiden Bio Science Park
J.H. Oortweg 21
Leiden, 2333 BD
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout Management Access: SF 2020
San Francisco, CA, United States,
January 13 –
January 16, 2020